InnovAtlasMalaria No More
Research institution

The Scripps Research Institute — Calibr-Skaggs Institute for Innovative Medicines

DiscoverDevelop

The Calibr-Skaggs Institute for Innovative Medicines at Scripps Research discovers and develops new malaria medicines, including long-acting injectable drugs designed to provide about three months of protection with a single dose.

1
Endemic countries
1
U.S. states
5
Products and programs
About

What they do

The Calibr-Skaggs Institute for Innovative Medicines at Scripps Research discovers and develops new malaria medicines, including long-acting injectable drugs designed to provide about three months of protection with a single dose.1,2 Its U.S. R&D is based in La Jolla, California.2 Its work spans discovery and preclinical development through the ReFRAME drug-repurposing platform and development of the long-acting injectable CBE161/MMV371 in partnership with Medicines for Malaria Venture (MMV).2

In the United States
Products and programs

In the field and in development

CBE161/MMV371 long-acting injectable licensed to MMV1,2
Kainomyx-Calibr next-generation antimalarial drug discovery collaboration3,2
Malaria Drug Accelerator (MalDA)2
ReFRAME drug-repurposing platform2
Long-acting injectable ivermectin for malaria vector control2
Where they work

Partnerships in 1 endemic country

Product testingResearch
Kenya
Africa
  • Kenya Medical Research Institute (KEMRI) Center for Clinical Research, Kisumu; Strathmore University Center for Research in Therapeutic Sciences, Nairobi; and WRAIR-Africa, Kisumu · collaborative antimalarial drug-discovery and repurposing research, including evaluation of compounds against P. falciparum2,4
U.S. partners

Who they work with in the United States

Sources

Where this comes from

  1. 1scripps.edu
  2. 2Confirmed by the organization
  3. 3scripps.edu
  4. 4link.springer.com